New hope for frail lung cancer patients: gentler combo therapy trial
NCT ID NCT04297605
Summary
This study is testing whether a combination of a single chemotherapy drug and an immunotherapy drug (pembrolizumab) is safe and effective for people with advanced non-small cell lung cancer who are too frail for standard, more intensive treatments. It aims to help patients who spend a significant part of the day resting or have limitations in daily activities. The main goal is to see if this gentler combination can control the cancer without causing severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester
NOT_YET_RECRUITINGRochester, New York, 14642, United States
-
University of Rochester
RECRUITINGRochester, New York, 14642, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.